免疫检查点阻断抗体的不良反应研究进展

Progress in Adverse Reactions of Immune Checkpoint Blocking Antibodies

免疫检查点阻断治疗是通过解除肿瘤细胞或其他免疫细胞上共抑制性分子对T细胞的抑制,从而恢复T细胞抗肿瘤免疫反应的治疗策略。程序性死亡受体-1、细胞毒性T淋巴细胞抗原-4作为研究最热的免疫检查点信号分子,其相应的阻断抗体在抗肿瘤临床治疗取得辉煌成果,并已被批准用于多种肿瘤的治疗。免疫相关副作用是免疫检查点抗体药物治疗过程中伴随出现的治疗目的以外的药理作用,鉴于免疫检查点抗体药物的广泛应用,有必要探讨免疫相关副作用的诊断及相应的处置方法。

Immune checkpoint therapy is a therapeutic strategy that restores T cell anti-tumor immune responses by relieving T cell suppression by tumor suppressor molecules on tumor cells or other immune cells.Programmed death receptor-1 and cytotoxic T lymphocyte antigen-4 as the main immune checkpoint signal molecules,itscorresponding blocking antibody has achieved brilliant results in clinical treatment,and has been approved for a variety of treatment of tumors.Immune-related side effects are the pharmacological effects beyond the therapeutic purposesthat accompany the immune checkpoint antibody drug treatment.Given the widespread use of immune checkpoint antibodies,it is necessary to investigate the diagnosis of immune-related side effects and the corresponding disposal methods.